Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statementDavid Taïeb, Karel Pacák, Roderick Clifton‐Bligh et al.|Nature Reviews Endocrinology|2023Cited by 95
Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and ParagangliomaJingjing Jiang, Graeme Eisenhofer, Jing Zhang et al.|The Journal of Clinical Endocrinology & Metabolism|2020Cited by 80
Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohortChristina Pamporaki, Graeme Eisenhofer, Annika M.A. Berends et al.|The Lancet Digital Health|2023Cited by 70
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trialÉric Baudin, Anouk van Berkel, Bernard Goichot et al.|The Lancet|2024Cited by 69
HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomasNicole Bechmann, Graeme Eisenhofer, Mats Leif Moskopp et al.|Endocrine Related Cancer|2020Cited by 59